Review: New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy

Journal of Zhejiang University: Science B

Volumn 13, Issue 1, 2012, Pages 56-82

  Tong, Jing ^a,b   Wang, You Wei ^b   Lu, Yuan An ^a,b  

^a UNIVERSITY OF HAWAII   (United States)

^b WUHAN UNIVERSITY   (China)

Author keywords

Clinical trial; Hepatitis C virus (HCV); Review; Small molecular compounds

Indexed keywords

2' C METHYL 7 DEAZA ADENOSINE; 2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; 2' METHYLCYTIDINE; 2' METHYLGUANOSINE MONOPHOSPHATE; 4' AZIDOCYTIDINE; ABT 072; ABT 333; ABT 450; ACH 1625; ALISPORIVIR; ALPHA INTERFERON; ALPHA1 INTERFERON; ANTIVIRUS AGENT; ASUNAPREVIR; AZD 7295; BALAPIRAVIR; BI 201335; BI 207127; BILB 1941; BMS 791325; BOCEPREVIR; DANOPREVIR; FILIBUVIR; GS 9256; GSK 625433; IDX 184; IDX 375; INX 189; MERICITABINE; MK 0608; MK 3281; NARLAPREVIR; NESBUVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; PSI 7851; PSI 7977; PSI 938; RIBAVIRIN; RITONAVIR; SETROBUVIR; SIMEPREVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; VANIPREVIR; VBY 376; VCH 222; VCH 759; VCH 916; VIRUS RNA; VX 813; ENZYME INHIBITOR;

ANEMIA; ANTIVIRAL ACTIVITY; APPETITE; CLINICAL TRIAL (TOPIC); DIZZINESS; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETHARGY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MENTAL DISEASE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS;

EID: 84856977406     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1100120     Document Type: Review

References (150)

1. Ali, S., Leveque, V., Le Pogam, S., Ma, H., Philipp, F., Inocencio, N., Smith, M., Alker, A., Kang, H., Najera, I., et al., 2008. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother., 52(12):4356-4369. [doi:10.1128/AAC.00444-08]
2. Bavisotto, L., Wang, C. C., Jacobson, I. M., Marcellin, P., Zeuzem, S., Lawitz, E. J., Lunde, M., Sereni, P., O'Brien, C., Oldach, D. W., et al., 2007. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects. Hepatology, 46(4):255A.
3. Bedard, J., Nicolas, O., Bilimoria, D., L'Heureux, L., Fex, P., David, M., Chan, L., 2009. Identification and characterization of VCH-222, a novel potent and selective non-nucleoside HCV polymerase inhibitor. J. Hepatol., 50 (S1): S340. [doi:10.1016/S0168-8278(09) 60937-5]
4. Boerner, J., Ma, S., Compton, T., Lin, K., 2007. NIM811, a cyclophilin inhibitor, and NM107, an HCV polymerase inhibitor, synergistically inhibits HCV replication and suppresses the emergence of resistance in vitro. Antivir. Res., 74(3):A57. [doi:10.1016/j.antiviral.2007.01.081]
5. Brown, N. A., 2009. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues. Expert Opin. Inv. Drugs, 18(6):709-725. [doi:10.1517/ 13543780902854194]
6. Burton, J. R., Everson, G. T., 2009. HCV NS5B polymerase inhibitors. Clin. Liver Dis., 13(3):453-465. [doi:10.1016/j.cld.2009.05.001]
7. Cai, Z., Zhang, C., Chang, K. S., Jiang, J., Ahn, B. C., Wakita, T., Liang, T. J., Luo, G., 2005. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J. Virol., 79(22):13963-13973. [doi:10.1128/JVI.79.22.13963-13973.2005] (Pubitemid 41552695)
8. Carroll, S. S., Ludmerer, S., Handt, L., Koeplinger, K., Zhang, N. R., Graham, D., Davies, M. E., MacCoss, M., Hazuda, D., Olsen, D. B., 2009. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virusinfected chimpanzees. Antimicrob. Agents Chemother., 53(3):926-934. [doi:10.1128/AAC.01032-08]
9. Chatterji, U., Lim, P., Bobardt, M. D., Wieland, S., Cordek, D. G., Vuagniaux, G., Chisari, F., Cameron, C. E., Targett-Adams, P., Parkinson, T., et al., 2010. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol., 53(1):50-56. [doi:10.1016/j.jhep. 2010.01.041]
10. Chauret, N., Chagnon-Labelle, C., Diallo, M., Laquerre, J., Laterreur, J., May, S., Ste-Marie, L., 2009. Preclinical pharmacokinetic and ADME characterization of VCH-222, a novel non-nucleoside HCV NS5B polymerase inhibitor. J. Hepatol., 50 (S1): S341-S342. [doi:10.1016/S0168-8278(09) 60941-7]
11. Chen, K. X., Njoroge, F. G., 2009. A review of HCV protease inhibitors. Curr. Opin. Investig. Drugs, 10(8):821-837.
12. Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., Houghton, M., 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244(4902):359-362. [doi:10.1126/science. 2523562] (Pubitemid 19117877)
13. Coelmont, L., Gallay, P., Bobardt, M., Kaptein, S., Paeshuyse, J., Vliegen, I., Vuagniaux, G., Neyts, J., 2009a. In vitro anti-hepatitis C virus (HCV) activities and resistance profile of Debio 025, a non-immunosuppressive cyclophilin binding molecule. Antivir. Res., 82(2):A20. [doi: 10.1016/j.antiviral.2009.02.024]
14. Coelmont, L., Gallay, P., Bobardt, M., Kaptein, S., Paeshuyse, J., Vliegen, I., Vuagniaux, G., Neyts, J., 2009b. Particular in vitro anti-HCV activities and resistance profile of the cyclophilin inhibitor Debio 025. J. Hepatol., 50 (S1): S36. [doi:10.1016/S0168-8278(09) 60090-8]
15. Coelmont, L., Hanoulle, X., Chatterji, U., Berger, C., Snoeck, J., Bobardt, M., Lim, P., Vliegen, I., Paeshuyse, J., Vuagniaux, G., et al., 2010. DEB025 (alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS ONE, 5(10): e13687. [doi:10.1371/journal.pone. 0013687]
16. Cooper, C., Lawitz, E. J., Ghali, P., Rodriguez-Torres, M., Anderson, F. H., Lee, S. S., Proulx, L., 2007. Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic hepatitis C patients: Results from a randomized, double-blind, placebo-controlled, ascending multiple dose study. Hepatology, 46(4):864A.
17. Cooper, C., Larouche, R., Bourgault, B., Chauret, N., Proulx, L., 2009a. Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor VCH-222 following single dose administration in healthy volunteers and antiviral activity in HCV-infected individuals. J. Hepatol., 50 (S1): S342. [doi:10.1016/S0168-8278(09) 60942-9]
18. Cooper, C., Lawitz, E. J., Ghali, P., Rodriguez-Torres, M., Anderson, F. H., Lee, S. S., Bedard, J., Chauret, N., Thibert, R., Boivin, I., et al., 2009b. Evaluation of VCH-759 monotherapy in hepatitis C infection. J. Hepatol., 51(1):39-46. [doi:10.1016/j.jhep. 2009.03.015]
19. Cretton-Scott, E., Perigaud, C., Peyrottes, S., Licklider, L., Camire, M., Larsson, M., La Colla, M., Hildebrand, E., Lallos, L., Bilello, J., et al., 2008. In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication. J. Hepatol., 48 (S2): S220. [doi: 10.1016/S0168-8278(08) 60590-5]
20. de Bruijne, J., Weegink, C. J., Jansen, P. L. M., Reesink, H. W., 2009. New developments in the antiviral treatment of hepatitis C. Vox Sanguinis, 97(1):1-12. [doi:10.1111/j. 1423-0410.2009.01187.x]
21. Delang, L., Coelmont, L., Neyts, J., 2010. Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses, 2(4):826-866. [doi:10.3390/v2040826]
22. Deutsch, M., Papatheodoridis, G. V., 2010. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection. Curr. Opin. Investig. Drugs, 11(8):951-963.
23. Feld, J. J., Hoofnagle, J. H., 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, 436(7053):967-972. [doi:10.1038/nature04082] (Pubitemid 41191673)
24. Fischer, G., Gallay, P., Hopkins, S., 2010. Cyclophilin inhibitors for the treatment of HCV infection. Curr. Opin. Investig. Drugs, 11(8):911-918.
25. Flisiak, R., Feinman, S. V., Jablkowski, M., Horban, A., Kryczka, W., Halota, W., Heathcote, J. E., Mazzella, G., Vandelli, C., Liz, J. S., et al., 2008a. Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon α-2a in treatment naive chronic HCV patients. J. Hepatol., 48 (S2): 62. [doi: 10.1016/S0168-8278(08) 60145-2]
26. Flisiak, R., Horban, A., Gallay, P., Bobardt, M., Selvarajah, S., Wiercinska-Drapalo, A., Siwak, E., Cielniak, I., Higersberger, J., Kierkus, J., et al., 2008b. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology, 47(3):817-826. [doi:10.1002/hep. 22131] (Pubitemid 351449673)
27. Flisiak, R., Woynarowski, M., Jablkowski, M., Halota, W., Kryczka, W., Horban, A., Czauz-Andrzejuk, A., Bialkowska, J., Pawlowska, M., Zarebska-Michaluk, D., et al., 2010. Efficacy of standard of care therapy following experimental Debio 025 treatment in patients with chronic hepatitis C. J. Hepatol., 52 (S1): S291. [doi:10.1016/S0168-8278(10) 60750-7]
28. Foy, E., Li, K., Sumpter, R. Jr., Loo, Y. M., Johnson, C. L., Wang, C., Fish, P. M., Yoneyama, M., Fujita, T., Lemon, S. M., et al., 2005. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. PNAS, 102(8):2986-2991. [doi:10.1073/pnas. 0408707102] (Pubitemid 40299903)
29. Franco, S., Parera, M., Aparicio, E., Clotet, B., Martinez, M. A., 2007. Genetic and catalytic efficiency structure of an HCV protease quasispecies. Hepatology, 45(4):899-910. [doi:10.1002/hep. 21623] (Pubitemid 46631559)
30. Franco, S., Clotet, B., Martinez, M. A., 2008. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals. Virus Res., 131(2):260-270. [doi:10.1016/j. virusres.2007.10.003] (Pubitemid 351173398)
31. Fridell, R. A., Qiu, D. K., Wang, C. F., Valera, L., Gao, M., 2010. Resistance analysis of the HCV NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother., 54(9):3641-3650. [doi:10.1128/AAC.00556- 10]
32. Friebe, P., Lohmann, V., Krieger, N., Bartenschlager, R., 2001. Sequences in the 5' nontranslated region of hepatitis C virus required for RNA replication. J. Virol., 75(24):12047-12057. [doi:10.1128/JVI.75.24.12047-12057. 2001] (Pubitemid 33115877)
33. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L. Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al., 2002. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 347(13):975-982. [doi:10.1056/NEJMoa020047]
34. Gaither, L. A., Borawski, J., Anderson, L. J., Balabanis, K. A., Devay, P., Joberty, G., Rau, C., Schirle, M., Bouwmeester, T., Mickanin, C., et al., 2010. Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology, 397(1):43-55. [doi:10.1016/j.virol. 2009. 10.043]
35. Galat, A., 2004. Function-dependent clustering of orthologues and paralogues of cyclophilins. Prot. Struct. Funct. Bioinf., 56(4):808-820. [doi:10.1002/prot.20156] (Pubitemid 39063322)
36. Gane, E., Foster, G. R., Cianciara, J., Stedman, C., Ryder, S., Buti, M., Clark, E., Tait, D., 2010a. Antiviral activity, pharmacokinetics, and tolerability of AZD7295, a novel NS5A inhibitor, in a placebo-controlled multiple ascending dose study in HCV genotype 1 and 3 patients. J. Hepatol., 52 (S1): S464. [doi:10.1016/S0168-8278(10) 61194-4]
37. Gane, E., Roberts, S., Stedman, C., Angus, P., Ritchie, B., Elston, R., Ipe, D., Morcos, P., Baher, L., Najera, I., et al., 2010b. Early on-treatment responses during pegylated IFN plus ribavirin are increased following 13 days of combination nucleoside polymerase (RG7128) and protease (RG7227) inhibitor therapy (INFORM-1). J. Hepatol., 52 (S1): S291-S292. [doi:10.1016/S0168-8278(10) 60751-9]
38. Gane, E. J., Roberts, S. K., Stedman, C. A., Angus, P. W., Ritchie, B., Elston, R., Ipe, D., Morcos, P. N., Baher, L., Najera, I., et al., 2010c. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebocontrolled, dose-escalation trial. Lancet, 376(9751):1467-1475. [doi:10.1016/S0140-6736(10) 61384-0]
39. Gane, E., Rouzier, R., Stedman, C., Wiercinska-Drapalo, A., Horban, A., Chang, L., Zhang, Y., Sampeur, P., Najera, I., Shulman, N., et al., 2010d. Ritonavir boosting of low dose RG7227/ITMN-191, HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens. J. Hepatol., 52 (S1): S16-S17. [doi:10.1016/S0168-8278(10) 60039-6]
40. Gane, E. J., Rodriguez-Torres, M., Nelson, D. E., Jacobson, I. M., McHutchison, J. G., Duca, A., Hyland, R., Hill, G., Albanis, E., Symonds, W. T., et al., 2010e. Sustained virologic response (SVR) following RG7128 1500 mg BID PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders. J. Hepatol., 52 (S1): S16. [doi:10.1016/S0168-8278(10) 60039-6]
41. Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J. H., O'Boyle, D. R., et al., 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature, 465(7294):96-100. [doi:10.1038/nature089960]
42. Goto, K., Watashi, K., Murata, T., Hishiki, T., Hijikata, M., Shimotohno, K., 2006. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem. Biophys. Res. Commun., 343(3):879-884. [doi:10.1016/j.bbrc.2006.03.059]
43. Grakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S. M., Rice, C. M., 1993. A second hepatitis C virus-encoded proteinase. PNAS, 90(22):10583-10587. [doi:10.1073/pnas.90.22.10583] (Pubitemid 23347086)
44. Hadziyannis, S. J., Sette, H. Jr., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H. Jr., Bernstein, D., Rizzetto, M., et al., 2004. Peginterferon-α 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med., 140(5):346-355.
45. Hayashi, N., Takehara, T., 2006. Antiviral therapy for chronic hepatitis C: past, present, and future. J. Gastroenterol., 41(1):17-27. [doi:10.1007/s00535-005-1740-7]
46. Herrmann, E., Kafer, A., Flisiak, R., Nicolas-Metral, V., Zeuzem, S., Crabbe, R., 2009. PK-PD modeling of viral kinetics during treatment with Debio-025 plus pegylated interferon α-2a in treatment-naive HCV patients. J. Hepatol., 50 (S1): S344. [doi:10.1016/S0168-8278(09) 60948-X]
47. Hezode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J. P., Bourliere, M., Gharakhanian, S., Bengtsson, L., et al., 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med., 360(18):1839-1850. [doi:10.1056/NEJMoa0807650]
48. Hopkins, S., Huang, Z. H., Scribner, A., Peel, M., 2009a. Antiviral activity of the non-immunosuppressive cyclophilin inhibitor SCY-635 in combination with investigational and approved anti-HCV agents. Hepatology, 50(4):1042A.
49. Hopkins, S., Heuman, D., Gavis, E., Lalezari, J., Glutzer, E., Di Massimo, B., Rusnak, P., Wring, S., Smitley, C., Ribeill, Y., 2009b. Safety, plasma pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection. J. Hepatol., 50 (S1): S36. [doi:10.1016/S0168-8278(09) 60091-X]
50. Hopkins, S., Scorneaux, B., Huang, Z. H., Murray, M. G., Wring, S., Smitley, C., Harris, R., Erdmann, F., Fischer, G., Ribeill, Y., 2010. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob. Agents Chemother., 54(2):660-672. [doi:10.1128/AAC.00660-09]
51. Horban, A., Berak, H., Kolakowska-Rzadzka, A., Patel, H., Flisiak, R., Crabbe, R., Liz, J. S., Heathcote, J. E., 2010. Sustained virological response after 4-week treatment with Debio 025 monotherapy or coadministered with PEG-IFN α-2a in HCV genotype 1 and 3 patients. J. Hepatol., 52 (S1): S294. [doi:10.1016/S0168-8278(10) 60757-X]
52. Houck, D. R., Hopkins, S., 2006. Preclinical evaluation of SCY-635, a cyclophilin inhibitor with potent anti-HCV activity. Hepatology, 44 (S1): 534A-535A.
53. Houghton, M., Abrignani, S., 2005. Prospects for a vaccine against the hepatitis C virus. Nature, 436(7053):961-966. [doi:10.1038/nature04081] (Pubitemid 41191672)
54. Inoue, K., Sekiyama, K., Yamada, M., Watanabe, T., Yasuda, H., Yoshiba, M., 2003. Combined interferon α-2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J. Gastroenterol., 38(6):567-572. [doi:10.1007/s00535-002-1104-5] (Pubitemid 36857388)
55. Inoue, K., Umehara, T., Ruegg, U. T., Yasui, F., Watanabe, T., Yasuda, H., Dumont, J. M., Scalfaro, P., Yoshiba, M., Kohara, M., 2007. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology, 45(4):921-928. [doi:10.1002/hep. 21587] (Pubitemid 46631561)
56. Jacobson, I., Pockros, P., Lalezari, J., Lawitz, E., Rodriguez-Torres, M., De Jesus, E., Haas, F., Martorell, C., Pruitt, R., Durham, K., et al., 2009. Antiviral activity of Filibuvir in combination with pegylated interferon α-2a and Ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1. J. Hepatol., 50 (S1): S382-S383. [doi:10.1016/S0168-8278(09) 61054-0]
57. Jacobson, I., Pockros, P. J., Lalezari, J., Lawitz, E., Rodriguez-Torres, M., De Jesus, E., Haas, F., Martorell, C., Pruitt, R., Purohit, V., et al., 2010. Virologic response rates following 4 weeks of Filibuvir in combination with pegylated interferon alfa-2a and Ribavirin in chronicallyinfected HCV genotype-1 patients. J. Hepatol., 52 (S1): S465. [doi:10.1016/S0168-8278(10) 61197-X]
58. Karakama, Y., Sakamoto, N., Itsui, Y., Nakagawa, M., Tasaka-Fujita, M., Nishimura-Sakurai, Y., Kakinuma, S., Oooka, M., Azuma, S., Tsuchiya, K., et al., 2010. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. Antimicrob. Agents Chemother., 54(8):3179-3186. [doi:10.1128/AAC.00113-10]
59. Ke, J., Lawitz, E., Rozier, R., Marbury, T., Nguyen, N., Serra, D., Dole, K., Praestgaard, J., Huang, M., Evans, T., 2009. Safety, and tolerability of NIM 811, a novel cyclophilin inhibitor for HCV, following single and multiple ascending doses in healthy volunteers and HCV-infected patients. J. Hepatol., 50 (S1): S229. [doi:10.1016/S0168-8278(09) 60624-3]
60. Kirkovsky, L., Zhou, Y., Norris, D., Okamoto, E., Nolan, T. G., Bartkowski, D., Khandurina, J., Sergeeva, M., Murphy, D., Ayida, B., et al., 2007. ANA598, a novel nonnucleoside inhibitor of HCV NS5B polymerase, exhibits favorable pharmacokinetic properties in multiple preclinical species. Hepatology, 46 (S1): 858A.
61. Klumpp, K., Smith, D., Brandl, M., Alfredson, T., Sarma, K., Smith, M., Najera, I., Jiang, W. R., Le Pogam, S., Leveque, V., et al., 2007. Design and characterization of R1626, a prodrug of the HCV replication inhibitor R1479 (4'-azidocytidine) with enhanced oral bioavailability. Antivir. Res., 74(3):A35. [doi:10.1016/j.antiviral.2007.01.029]
62. Kolykhalov, A. A., Mihalik, K., Feinstone, S. M., Rice, C. M., 2000. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J. Virol., 74(4):2046-2051. [doi:10.1128/JVI.74.4.2046-2051.2000] (Pubitemid 30434065)
63. Kukolj, G., Benhamou, Y., Manns, M. P., Bourliere, M., Pol, S., Schuchmann, M., Cartier, M., Huang, D., Lagace, L., Steinmann, G., et al., 2009. BI 201335, a potent HCV NS3 protease inhibitor, in treatment-naive and-experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain. J. Hepatol., 50 (S1): S347. [doi:10.1016/S0168-8278(09) 60956-9]
64. Kukolj, G., Bousquet, C., Dansereau, N., Do, F., Lagace, L., Llinas-Brunet, M., Marquis, M., Massariol, M. J., Maurice, R., Spickler, C., et al., 2010. Characterization of resistant mutants selected in vitro by the HCV NS3/4A protease inhibitor BI 201335. J. Hepatol., 52 (S1): S295. [doi:10.1016/S0168-8278(10) 60760-X]
65. Kwo, P. Y., Lawitz, E. J., McCone, J., Schiff, E. R., Vierling, J. M., Pound, D., Davis, M. N., Galati, J. S., Gordon, S. C., Ravendhran, N., et al., 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon α-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an openlabel, randomised, multicentre phase 2 trial. Lancet, 376(9742):705-716. [doi:10.1016/S0140-6736(10) 60934-8]
66. Lalezari, J., Asmuth, D., Casiro, A., Vargas, H. E., Patrick, G. D., Liu, W., Pietropaolo, K., Zhou, X. J., Sullivan-Bolyai, J., Mayers, D. L., 2009. Antiviral activity, safety and pharmacokinetics of IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. Hepatology, 50(6):11A-12A.
67. Lallos, L., La Colla, M., Serra, I., Bilello, J. P., Soubasakos, M. A., Li, B., Panzo, R. J., Gillum, J. M., Bonin, A., Seifer, M., et al., 2009. Combination of IDX184, a nucleotide prodrug polymerase inhibitor, with other classes of HCV inhibitors is additive to synergistic in the HCV replicon in vitro. Hepatology, 50(4):1045A.
68. Lam, A. M., Frick, D. N., 2006. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J. Virol., 80(1):404-411. [doi:10.1128/JVI.80.1.404-411.2006]
69. Larrey, D., Benhamou, Y., Lohse, A. W., Trepo, C., Moelleken, C., Bronowicki, J. P., Heim, M. H., Arasteh, K., Zarski, J. P., Bourliere, M., et al., 2009a. BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C. Hepatology, 50(4):1044A.
70. Larrey, D., Benhamou, Y., Lohse, A. W., Trepo, C., Moelleken, C., Bronowicki, J. P., Arasteh, K., Bourliere, M., Heim, M., Enriquez, J., et al., 2009b. Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J. Hepatol., 50 (S1): S383-S384. [doi:10.1016/S0168-8278(09) 61056-4]
71. Lavanchy, D., 2009. The global burden of hepatitis C. Liver Int., 29(1):74-81. [doi:10.1111/j.1478-3231.2008.01934.x]
72. Lawitz, E., Rouzier, R., Nguyen, T., Huang, M., Ke, J., Praestgaard, J., Serra, D., Koziel, M., Evans, T., 2009. Safety and antiviral efficacy of 14 days of the cycophilin inhibitor NIM811 in combination with pegylated interferon α-2a in relapsed genotype 1 HCV infected patients. J. Hepatol., 50 (S1): S379. [doi:10.1016/S0168-8278(09) 61047-3]
73. Lawitz, E. J., Marbury, T. C., Vince, B. D., Grunenberg, N., Rodriguez-Torres, M., de Micco, M. P., Tarro, J. N., Shelton, M. J., West, S., Zong, J., et al., 2010. Doseranging, three-day monotherapy study of the HCV NS3 protease inhibitor GS-9256. J. Hepatol., 52 (S1): S466-S467. [doi:10.1016/S0168-8278(10) 61199-3]
74. Lawitz, E., Rodriquez-Torres, M., Rustgi, V. K., Hassanein, T., Rahimy, M. H., Crowley, C. A., Freddo, J. L., Muir, A., McHutchison, J., 2010a. Safety and antiviral activity of ANA598 in combination with pegylated interferon α-2a plus ribavirin in treatment-naive genotype-1 chronic HCV patients. J. Hepatol., 52 (S1): S467. [doi:10.1016/S0168-8278(10) 61200-7]
75. Le Pogam, S., Seshaadri, A., Ewing, A., Kang, H. S., Kosaka, A., Yan, J. M., Berrey, M., Symonds, B., de la Rosa, A., Cammack, N., et al., 2010. RG7128 alone or in combination with pegylated interferon-α 2a and ribavirin pre-1vents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J. Infect. Dis., 202(10):1510-1519. [doi:10.1086/656774]
76. Lemke, C. T., Zhao, S. P., Goudreau, N., Hucke, O., Thibeault, D., Llinas-Brunet, M., White, P. W., 2010. Bound structure and biochemical mechanism of action of BI 201335, a potent, non-covalent inhibitor of HCV NS3-NS4A protease. Antivir. Res., 86(1):A20-A21. [doi:10.1016/j. antiviral.2010.02.336]
77. Levin, J., Eley, T., Pasquinelli, C., Wendelburg, P., Villegas, C., He, B., Liao, S., Jiang, H., Marbury, T., Bertz, R., et al., 2010. Safety and Pharmacokinetics of BMS-650032 Following Multiple Ascending Doses for 14 Days in Healthy Subjects. Bristol-Myers Squibb, Princeton, FL.
78. Li, H., Tatlock, J., Linton, A., Gonzalez, J., Jewell, T., Patel, L., Ludlum, S., Drowns, M., Rahavendran, S. V., Skor, H., et al., 2009. Discovery of (R)-6-cyclopentyl-6-(2-(2, 6-diethylpyridin-4-yl) ethyl)-3-((5, 7-dimethyl-[1, 2, 4]triazolo [1, 5-a]pyrimidin-2-yl) methyl)-4-hydroxy-5, 6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J. Med. Chem., 52(5):1255-1258. [doi:10.1021/jm8014537]
79. Lin, C., Kwong, A. D., Perni, R. B., 2006. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets, 6(1):3-16. [doi:10.2174/ 187152606776056706] (Pubitemid 43796632)
80. Lin, K., Kwong, A. D., Lin, C., 2004. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and α interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob. Agents Chemother., 48(12):4784-4792. [doi:10.1128/AAC.48.12.4784- 4792.2004] (Pubitemid 39577685)
81. Lin, K., Perni, R. B., Kwong, A. D., Lin, C., 2006. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob. Agents Chemother., 50(5):1813-1822. [doi:10.1128/AAC.50.5.1813-1822.2006]
82. Lin, T. L., Lenz, O., Fanning, G., Verbinnen, T., Delouvroy, F., Scholliers, A., Vermeiren, K., Rosenquist, A., Edlund, M., Samuelsson, B., et al., 2009. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob. Agents Chemother., 53(4):1377-1385. [doi:10.1128/AAC.01058-08]
83. Lindenbach, B. D., Evans, M. J., Syder, A. J., Wolk, B., Tellinghuisen, T. L., Liu, C. C., Maruyamam, T., Hynes, R. O., Burton, D. R., McKeating, J. A., et al., 2005. Complete replication of hepatitis C virus in cell culture. Science, 309(5734):623-626. [doi:10.1126/science.1114016] (Pubitemid 41033648)
84. Liu-Young, G., Kozal, M. J., 2008. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care St., 22(6):449-457. [doi:10.1089/apc.2007.0199]
85. Liverton, N. J., Carroll, S. S., Dimuzio, J., Fandozzi, C., Graham, D. J., Hazuda, D., Holloway, M. K., Ludmerer, S. W., McCauley, J. A., McIntyre, C. J., et al., 2010. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob. Agents Chemother., 54(1):305-311. [doi:10.1128/AAC.00677-09]
86. Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., Bartenschlager, R., 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 285(5424):110-113. [doi:10.1126/science.285.5424. 110] (Pubitemid 29307577)
87. Lok, A. S., Gardiner, D. F., Lawitz, E., Martorell, C., Everson, G. T., Ghalib, R. H., Reindollar, R., Rustgi, V. K., Wendelburg, P., Zhu, K., et al., 2010. Combination therapy with BMS-790052 and BMS-650032 alone or with pegylated interferon and ribavirin (PEGIFN/RBV) results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. Hepatology, 52(4):877A.
88. Ma, S., Boerner, J. E., TiongYip, C., Weidmann, B., Ryder, N. S., Cooreman, M. P., Lin, K., 2006. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with α interferon. Antimicrob. Agents Chemother., 50(9):2976-2982. [doi: 10.1128/AAC.00310-06] (Pubitemid 44396401)
89. Malcolm, B. A., Liu, R., Lahser, F., Agrawal, S., Belanger, B., Butkiewicz, N., Chase, R., Gheyas, F., Hart, A., Hesk, D., et al., 2006. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of α interferon in replicon cells. Antimicrob. Agents Chemother., 50(3):1013-1020. [doi:10.1128/AAC.50.3.1013-1020.2006] (Pubitemid 43327807)
90. Manns, M., Reesink, H., Moreno, C., Berg, T., Benhamou, Y., Horsmans, Y., Dusheiko, G., Flisiak, R., Meyvisch, P., Lenz, O., et al., 2009. Opera-1 Trial: interim analysis of safety and antiviral activity of TMC435 in treatmentnaive genotype 1 HCV patients. J. Hepatol., 50 (S1): S7. [doi:10.1016/S0168-8278(09) 60013-1]
91. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M., Albrecht, J. K., 2001. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358(9286):958-965. [doi:10.1016/S0140-6736(01) 06102-5] (Pubitemid 32913521)
92. Manns, M. P., Foster, G. R., Rockstroh, J. K., Zeuzem, S., Zoulim, F., Houghton, M., 2007. The way forward in HCV treatment-finding the right path. Nat. Rev. Drug Discov., 6(12):991-1000. [doi:10.1038/nrd2411] (Pubitemid 350201789)
93. McCauley, J. A., McIntyre, C. J., Rudd, M. T., Nguyen, K. T., Romano, J. J., Butcher, J. W., Gilbert, K. F., Bush, K. J., Holloway, M. K., Swestock, J., et al., 2010. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4A protease inhibitor. J. Med. Chem., 53(6):2443-2463. [doi:10.1021/ jm9015526]
94. McCown, M. F., Rajyaguru, S., le Pogam, S., Ali, S., Jiang, W. R., Kang, H., Symons, J., Cammack, N., Najera, I., 2008. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother., 52(5):1604-1612. [doi:10.1128/AAC. 01317-07] (Pubitemid 351614649)
95. McPhee, F., 2010. Identification and preclinical profile of the novel HCV NS3 protease inhibitor BMS-650032. J. Hepatol., 52 (S1): S296. [doi:10.1016/S0168-8278(10) 60763-5]
96. McPhee, F., Hernandez, D., Sheaffer, A., Lee, M., Falk, P., Yu, F., Zhai, G. Z., Chaniewski, S., Pasquinelli, C., 2009. Genotypic and phenotypic analysis of samples from HCV-infected subjects treated with BMS-650032 in a single ascending dose study. Hepatology, 50 (S4): 1048A. [doi:10.1002/hep. 23307]
97. Mori, J., Hammond, J. L., Srinivasan, S., Jagannatha, S., van der Ryst, E., 2010. Genotypic characterisation of filibuvir (PF-00868554) resistance in patients receiving four weeks co-administration of filibuvir with PEGIFN/RBV (12 week analysis). J. Hepatol., 52 (S1): S15. [doi:10.1016/S0168-8278(10) 60037-2]
98. Moucari, R., Forestier, N., Larrey, D., Guyader, D., Couzigou, P., Benhamou, Y., Voitot, H., Vidaud, M., Seiwert, S., Bradford, B., et al., 2010. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut, 59(12):1694-1698. [doi:10.1136/gut.2010.219089]
99. Neelakantan, S., Purohit, V. S., O'Gorman, M., Hammond, J., Tensfeldt, T. G., 2010. Exposure-response relationship of Filibuvir in HCV infected patients: application to dose selection for combination therapy. J. Hepatol., 52 (S1): S119-S120. [doi:10.1016/S0168-8278(10) 60288-7]
100. Nguyen, M. H., Keeffe, E. B., 2005. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin. Gastroenterol. Hepatol., 3(10):S97-S101. [doi:10.1016/S1542-3565(05) 00711-1] (Pubitemid 41427738)
101. Nicolas, O., Boivin, I., St-Denis, C., Bedard, J., 2008. Genotypic analysis of HCV NS5B variants selected from patients treated with VCH-759. J. Hepatol., 48 (S2): S317. [doi:10.1016/S0168-8278(08) 60846-6]
102. Ohno, T., Mizokami, M., Tibbs, C. J., Ohba, K., Suzuki, K., Wu, R. R., Nouri-Aria, K. T., Williams, R., 1994. New genotype of hepatitis C virus in South Africa. J. Med. Virol., 42(4):409-413. [doi:10.1002/jmv. 1890420414] (Pubitemid 24128138)
103. Opar, A., 2010. Excitement grows for potential revolution in hepatitis C virus treatment. Nat. Rev. Drug Discov., 9(7):501-503. [doi:10.1038/nrd3214]
104. Otto, M. J., Robson, R., Rodríguez, C. A., Beard, A., Symonds, W. T., Hill, G., Berrey, M. M., 2007. Pharmacokinetics, Safety, and Tolerability of R7128, a Novel Nucleoside Polymerase Inhibitor for HCV Following Single, Ascending Oral Doses in Healthy Volunteers. Pharmasset Inc., Princeton, NJ.
105. Paeshuyse, J., Kaul, A., de Clercq, E., Rosenwirth, B., Dumont, J. M., Scalfaro, P., Bartenschlager, R., Neyts, J., 2006. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology, 43(4):761-770. [doi:10.1002/hep. 21102]
106. Patel, R., Thompson, P., Showalter, R., Appleman, J., 2010. In vitro combination studies of ANA598 with anti-HCV agents demonstrate enhanced anti-viral activity. Antivir. Res., 86(1):A41-A42. [doi:10.1016/j.antiviral. 2010.02.397]
107. Pawlotsky, J. M., 2006. Therapy of hepatitis C: from empiricism to eradication. Hepatology, 43 (S1): S207-S220. [doi:10.1002/hep. 21064]
108. Perni, R. B., Almquist, S. J., Byrn, R. A., Chandorkar, G., Chaturvedi, P. R., Courtney, L. F., Decker, C. J., Dinehart, K., Gates, C. A., Harbeson, S. L., et al., 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother., 50(3):899-909. [doi:10.1128/AAC.50.3.899-909.2006] (Pubitemid 43327793)
109. Pockros, P., Nelson, D., Godofsky, E., Rodriguez-Torres, M., Everson, G. T., Fried, M. W., Ghalib, R., Harrison, S., Nyberg, L., Shiffman, M. L., et al., 2008a. High relapse rate seen at week 72 for patients treated with R1626 combination therapy. Hepatology, 48(4):1349-1350. [doi:10.1002/hep. 22593]
110. Pockros, P. J., Nelson, D., Godofsky, E., Rodriguez-Torres, M., Everson, G. T., Fried, M. W., Ghalib, R., Harrison, S., Nyberg, L., Shiffman, M. L., et al., 2008b. R1626 plus peginterferon α-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology, 48(2):385-397. [doi:10.1002/hep. 22357]
111. Pol, S., Everson, G., Ghalib, R., Rustgi, V., Martorell, C., Tatum, H. A., Lim, J., Hezode, C., Diva, U., Yin, P. D., et al., 2010. Once-daily NS5A inhibitor (BMS-790052) plus peginterferon α-2a and Ribavirin produces high rates of extended rapid virologic response in treatment-naive HCV-genotype 1 subjects: phase 2a trial. J. Hepatol., 52 (S1): S462. [doi:10.1016/S0168- 8278(10) 61190-7]
112. Rahimy, M. H., Crowley, C. A., Freddo, J. L., Sergeeva, M. V., Golec, B., 2008. Results of a phase I safety, tolerability and pharmacokinetic study of ANA598, a non-nucleoside NS5B polymerase inhibitor, in healthy volunteers. Hepatology, 48(4):1026A.
113. Reddy, R., Rodriguez-Torres, M., Gane, E., Robson, R., Lalezari, J., Everson, G. T., Dejesus, E., McHutchison, J. G., Vargas, H. E., Beard, A., et al., 2007. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology, 46(4):862A-863A.
114. Reesink, H. W., Fanning, G. C., Farha, K. A., Weegink, C., van Vliet, A., van't Klooster, G., Lenz, O., Aharchi, F., Marien, K., van Remoortere, P., et al., 2010. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology, 138(3):913-921. [doi:10.1053/j.gastro.2009.10.033]
115. Reiser, M., Timm, J., 2009. Serine protease inhibitors as antihepatitis C virus agents. Expert Rev. Anti.-Infect. Ther., 7(5):537-547. [doi:10.1586/eri.09.30]
116. Reiser, M., Hinrichsen, H., Benhamou, Y., Reesink, H. W., Wedemeyer, H., Avendano, C., Riba, N., Yong, C. L., Nehmiz, G., Steinmann, G. G., 2005. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology, 41(4):832-835. [doi:10.1002/hep. 20612] (Pubitemid 40462946)
117. Roberts, S. K., Cooksley, G., Dore, G. J., Robson, R., Shaw, D., Berns, H., Hill, G., Klumpp, K., Najera, I., Washington, C., 2008. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology, 48(2):398-406. [doi:10.1002/hep. 22321]
118. Salmon-Ceron, D., Lewden, C., Morlat, P., Bevilacqua, S., Jougla, E., Bonnet, F., Heripret, L., Costagliola, D., May, T., Chene, G., 2005. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J. Hepatol., 42(6):799-805. [doi:10.1016/j.jhep. 2005.01.022] (Pubitemid 40693195)
119. Sarrazin, C., Rouzier, R., Wagner, F., Forestier, N., Larrey, D., Gupta, S. K., Hussain, M., Shah, A., Cutler, D., Zhang, J., et al., 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders. Gastroenterology, 132(4):1270-1278. [doi:10.1053/j.gastro.2007.01.041] (Pubitemid 46627577)
120. Schiff, E., Poordad, F. F., Jacobson, I. M., Flamm, S. L., Bacon, B. R., Lawitz, E. J., Gordon, S. R., McHutchison, J. G., Ghalib, R., Poynard, T., et al., 2008. Role of interferon response during RE-Treatment of null responders with boceprevir combination therapy: results of phase II trial. Gastroenterology, 134(4):A755. [doi:10.1016/S0016-5085(08) 63527-1]
121. Schmitz, U., Tan, S. L., 2008. NS5A-from obscurity to new target for HCV therapy. Recent Pat. Anti-Infect. Drug Discov., 3(2):77-92. [doi:10.2174/ 157489108784746597]
122. Seth, R. B., Sun, L., Chen, Z. J., 2006. Antiviral innate immunity pathways. Cell Res., 16(2):141-147. [doi:10.1038/sj.cr. 7310019] (Pubitemid 43247969)
123. Shepard, C. W., Finelli, L., Alter, M. J., 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis., 5(9):558-567. [doi:10.1016/S1473-3099(05) 70216-4] (Pubitemid 41196755)
124. Shi, S. T., Herlihy, K. J., Graham, J. P., Nonomiya, J., Rahavendran, S. V., Skor, H., Irvine, R., Binford, S., Tatlock, J., Li, H., et al., 2009. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother., 53(6):2544-2552. [doi: 10.1128/AAC.01599-08]
125. Shih, I. H., Vliegen, I., Peng, B., Yang, H., Paeshuyse, J., Purstinger, G., Fenaux, M., Mabery, E., Bahador, G., Lehman, L. S., et al., 2007. Mechanistic characterization of GS-9190, a novel non-nucleoside inhibitor of HCV NS5B polymerase with potent antiviral activity and a unique mechanism of action. Hepatology, 46(4):859A.
126. Simmonds, P., 2004. Genetic diversity and evolution of hepatitis C virus-15 years on. J. Gen. Virol., 85(11):3173-3188. [doi:10.1099/vir.0.80401-0] (Pubitemid 39445434)
127. Stauber, K., Marlor, C. W., Mushtaq, G., Gadhachanda, V., Pais, G., Hashimoto, A., Phadke, A., Huang, M., Deshpande, M., 2010. Characterization of the hepatoselective distribution of ACH-1625, a potent, clinical stage HCV NS3 protease inhibitor. J. Hepatol., 52 (S1): S299. [doi:10.1016/S0168-8278(10) 60772-6]
128. Susan, H., 2010. Gilead's Investigational Hepatitis C Compounds GS 9190 and GS 9256 in Combination with Standard of Care Therapies Achieve Substantial Viral Suppression in Phase II Study. Available from http://www.gilead.com/pr- 1489408 [Accessed on Nov. 20, 2011]
129. Tang, H., Grise, H., 2009. Cellular and molecular biology of HCV infection and hepatitis. Clin. Sci., 117(2):49-65. [doi:10.1042/CS20080631]
130. Tellinghuisen, T. L., Foss, K. L., 2008. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog., 4(3): e1000032. [doi:10.1371/journal.ppat.1000032] (Pubitemid 351631090)
131. Thompson, P. A., Patel, R., Showalter, R. E., Li, C., Applemon, J. R., Steffy, K., 2008. In vitro studies demonstrate that combinations of antiviral agents that include HCV polymerase inhibitor ANA598 have the potential to overcome viral resistance. Hepatology, 48(4):1164A.
132. Thompson, P., Patel, R., Steffy, K., Appleman, J., 2009. Preclinical studies of ANA598 combined with other anti-HCV agents demonstrate potential of combination treatment. J. Hepatol., 50 (S1): S37. [doi:10.1016/S0168-8278(09) 60092-1]
133. Thompson, P., Showalter, R., Patel, R., Appleman, J., 2010a. In vitro combination of ANA598 with other anti-HCV agents can eliminate the emergence of resistant colonies. Antivir. Res., 86(1):A48. [doi:10.1016/j.antiviral.2010. 02.415]
134. Thompson, P. A., Showalter, R. E., Patel, R. A., Appleman, J. R., 2010b. Enhanced in vitro antiviral activity of ANA598 in combination with other anti-HCV Agents support combination treatment. J. Hepatol., 52 (S1): S262. [doi:10.1016/S0168-8278(10) 60675-7]
135. Tong, X., Arasappan, A., Bennett, F., Chase, R., Feld, B., Guo, Z., Hart, A., Madison, V., Malcolm, B., Pichardo, J., et al., 2010. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. Antimicrob. Agents Chemother., 54(6):2365-2370. [doi:10.1128/AAC. 00135-10]
136. Troke, P., Lewis, M., Simpson, P., van der Ryst, E., Hammond, J., Craig, C., Perros, M., Westby, M., 2009. Genotypic characterisation of HCV NS5B following 8-day monotherapy with the polymerase inhibitor PF-00868554 in HCV-infected subjects. J. Hepatol., 50 (S1): S351. [doi:10.1016/S0168-8278(09) 60970-3]
137. Vliegen, I., Paeshuyse, J., Marbery, E., Peng, B., Shih, H., Lehman, L. S., Dutartre, H., Selisko, B., Canard, B., Bondy, S., et al., 2007. GS-9190, a novel substituted imidazopyridine analogue, is a potent inhibitor of hepatitis C virus replication in vitro and remains active against known drug resistant mutants. Hepatology, 46(4):855A.
138. Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Krausslich, H. G.
139. Mizokami, M., et al., 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med., 11(7):791-796. [doi:10.1038/nm1268] (Pubitemid 41021213)
140. Walker, M. P., Hong, Z., 2002. HCV RNA-dependent RNA polymerase as a target for antiviral development. Cur. Opin. Pharmacol., 2(5):534-540. [doi:10.1016/S1471-4892(02) 00195-9]
141. Wang, C., Sarnow, P., Siddiqui, A., 1993. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J. Virol., 67(6):3338-3344. (Pubitemid 23143708)
142. Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M., Shimotohno, K., 2003. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology, 38(5):1282-1288. [doi:10.1053/jhep. 2003.50449] (Pubitemid 37314838)
143. Weisberg, I. S., Jacobson, I. M., 2009. Telaprevir: hope on the horizon, getting closer. Clin. Liver Dis., 13(3):441-452. [doi:10.1016/j.cld.2009.05.009]
144. White, P. W., Llinas-Brunet, M., Amad, M., Bethell, R. C., Bolger, G., Cordingley, M. G., Duan, J. M., Garneau, M., Lagace, L., Thibeault, D., et al., 2010a. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob. Agents Chemother., 54(11):4611-4618. [doi:10.1128/AAC.00787-10]
145. White, P. W., Llinas-Brunet, M., Amad, M., Bolger, G., Cordingley, M. G., Duan, J., Garneau, M., Lagace, L., Thibeault, D., Kukolj, G., 2010b. Preclinical characterization of non-covalent HCV NS3/4A protease inhibitor BI 201335. J. Hepatol., 52 (S1): S302. [doi:10.1016/S0168-8278(10) 60779-9]
146. Wong, D. A., Tong, L. K., Lim, W., 1998. High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong. Eur. J. Epidemiol., 14(5):421-426. [doi:10.1023/A:1007400304726] (Pubitemid 28370776)
147. Yang, C., Wang, Y., Wieman, L., Eisenberg, E., Lee, M., Murray, B., Tong, L., Ray, A., Bondy, S., Tse, W., et al., 2007. Preclinical pharmacokinetic characterization of GS-9190, a novel non-nucleoside HCV NS5B polymerase inhibitor. Hepatology, 46(4):860A-861A.
148. Yi, M., Lemon, S. M., 2003. 3'-nontranslated RNA signals required for replication of hepatitis C virus RNA. J. Virol., 77(6):3557-3568. [doi:10.1128/JVI.77.6.3557-3568.2003] (Pubitemid 36297275)
149. Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D. R., Wielandm, S. F., Uprichard, S. L., Wakita, T., Chisari, F. V., 2005. Robust hepatitis C virus infection in vitro. PNAS, 102(26):9294-9299. [doi:10.1073/pnas. 0503596102] (Pubitemid 40923557)
150. Zhou, X. J., Pietropaolo, K., Sullivan-Bolyai, J., Kuca, B., Liu, W., Xu, L., Belanger, B., Khan, S., Mayers, D., 2009. IDX184, a liver-targeted nucleotide HCV polymerase inhibitor: results of a first-in-man safety and pharmacokinetic study. J. Hepatol., 50 (S1): S351. [doi:10.1016/S0168-8278(09) 60968-5]X